The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Current and emerging strategies for targeting NETs
Rocio Garcia-Carbonero, MD, PhD, University Hospital 12 De Octubre, Madrid, Spain, discusses current and emerging systemic therapies for the treatment of neuroendocrine tumors (NETs). Current systemic therapies for NETs include somatostatin analogues, somatostatin-targeting radioligands, angiogenesis inhibitors and mTOR inhibitors, with treatment options differing by primary tumor site. Dr Garcia-Carbonero also explores areas of current research, including optimization of sequencing strategies, new radioligand therapies such as 225Ac-DOTATATE and 212Pb-DOTAMTATE, a new angiogenesis inhibitor and head-to-head trials which aim to directly compare current therapies. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
